Skip to content

Study · Observational study · n = 32 · 2018

3 results

Changes in bone mineral density and bone turnover markers during treatment with teriparatide in pregnancy- and lactation-associated osteoporosis.

Hong N, Kim JE, Lee SJ, Kim SH, Rhee Y

Clinical endocrinology22 Feb 2018Cited by 41 (Europe PMC)

PMID29389010 (opens in a new tab)DOI10.1111/cen.13557 (opens in a new tab)PepBankPUB-29389010
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In pregnancy- and lactation-associated osteoporosis, teriparatide was linked to greater lumbar spine BMD increases than untreated controls.

    In plain wordsIn pregnancy- and lactation-associated osteoporosis, teriparatide was linked to greater spine bone density increases than no treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseLumbar spine BMD increase
    Study

    n = 32

    Comparator
    Untreated controls
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg daily · subcutaneous · 12 monthsAs given in this study (human).

    Measurements

    LSBMD increase
    15.5%
    teriparatide
    LSBMD increase
    7.5%
    controls

    Source sentences

    Summary
    LSBMD increased in both subjects treated with TPTD and controls, with greater increases in the TPTD group (15.5 ± 6.6% vs 7.5 ± 7.1%, P = .020) after adjustment for age and baseline LSBMD.
    4 context sentences
    Summary · context
    Retrospective cohort study.
    Summary · context
    Thirty-two patients with PLO who presented with multiple vertebral fractures to a tertiary institution between 2007 and 2015 were included.
    Summary · context
    Changes in BMD at the lumbar spine (LSBMD) and proximal femur after 12 months of daily subcutaneous injections of 20 μg TPTD (n = 27) were assessed.
    Summary · context
    Subjects who rejected the TPTD treatment were used as controls (n = 5).
  2. 02HumanObservational studyEfficacy outcome

    In patients with pregnancy- and lactation-associated osteoporosis, serum osteocalcin increased significantly during teriparatide treatment.

    In plain wordsIn pregnancy- and lactation-associated osteoporosis, teriparatide treatment was linked to increased blood osteocalcin.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSerum osteocalcin
    Study

    n = 27

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg daily · subcutaneous · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    During follow-up, serum levels of osteocalcin (OCN) and C-telopeptide of type I collagen (CTX) increased significantly in the TPTD group.
    4 context sentences
    Summary · context
    Retrospective cohort study.
    Summary · context
    Thirty-two patients with PLO who presented with multiple vertebral fractures to a tertiary institution between 2007 and 2015 were included.
    Summary · context
    Changes in BMD at the lumbar spine (LSBMD) and proximal femur after 12 months of daily subcutaneous injections of 20 μg TPTD (n = 27) were assessed.
    Summary · context
    Subjects who rejected the TPTD treatment were used as controls (n = 5).
  3. 03HumanObservational studyEfficacy outcome

    In patients with pregnancy- and lactation-associated osteoporosis, serum CTX increased significantly during teriparatide treatment.

    In plain wordsIn pregnancy- and lactation-associated osteoporosis, teriparatide treatment was linked to increased blood CTX.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSerum CTX
    Study

    n = 27

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg daily · subcutaneous · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    During follow-up, serum levels of osteocalcin (OCN) and C-telopeptide of type I collagen (CTX) increased significantly in the TPTD group.
    4 context sentences
    Summary · context
    Retrospective cohort study.
    Summary · context
    Thirty-two patients with PLO who presented with multiple vertebral fractures to a tertiary institution between 2007 and 2015 were included.
    Summary · context
    Changes in BMD at the lumbar spine (LSBMD) and proximal femur after 12 months of daily subcutaneous injections of 20 μg TPTD (n = 27) were assessed.
    Summary · context
    Subjects who rejected the TPTD treatment were used as controls (n = 5).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.